Surgically resected human tumors reveal the biological significance of the gastric cancer stem cell markers CD44 and CD26

SHIMPEI NISHIKAWA^{1,2}, MASAMITSU KONNO¹, ATSUSHI HAMABE^{1,2}, SHINICHIRO HASEGAWA^{1,2}, YOSHIHIRO KANO^{1,2}, TAKAHITO FUKUSUMI³, TAROH SATOH¹, SHUJI TAKIGUCHI², MASAKI MORI², YUICHIRO DOKI² and HIDESHI ISHII¹

Departments of ¹Frontier Science for Cancer and Chemotherapy, ²Gastroenterological Surgery and ³Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan

Received March 9, 2014; Accepted August 29, 2014

DOI: 10.3892/ol.2015.3063

Abstract. Cancer tissue is maintained by relatively small populations of cancer stem cells (CSCs), which are involved in chemotherapy resistance, recurrence and metastasis. As tumor tissues are comprised of various cells, studies of human clinical samples are important for the characterization of CSCs. In the present study, an expression profiling study was performed in which an anti-cell surface marker antibody-based array platform, a flow cytometry-based cell separation technique and a tumorigenicity analysis in immunodeficient animals were utilized. These approaches revealed that the markers cluster of differentiation (CD)44 and CD26 facilitated the fractionation of surgically resected human gastric cancer (GC) cells into the following subset populations with distinct tumorigenic potentials: Highly tumorigenic CD26+CD44+ cells (6/6 mice formed tumors), moderately tumorigenic CD26⁺CD44⁻ cells (5/6 mice formed tumors), and weakly or non-tumorigenic CD26⁻CD44⁻ cells (2/6 mice formed tumors). Furthermore, exposure to 5-fluorouracil significantly increased the proportion of CD26⁺ cells in vitro. The present study demonstrated that the combined expression of CD26 and CD44 presents a potential marker of human GC stem cells.

Correspondence to: Dr Masaki Mori, Department of Gastrointestinal Surgery, Graduate School of Medicine, Osaka University, 2-2 (E2) Yamadaoka, Suita, Osaka 565-0871, Japan E-mail: mmori@gesurg.med.osaka-u.ac.jp

Dr Hideshi Ishii, Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 2-2 (E2) Yamadaoka, Suita, Osaka 565-0871, Japan E-mail: hishii@gesurg.med.osaka-u.ac.jp

Key words: gastric cancer, cancer stem cell, tumor-initiating cell, chemotherapy, CD44, CD26

Introduction

More than 800,000 mortalities occur annually as a result of gastric cancer (GC), which is the second leading cause of cancer-associated mortality worldwide (1). Although the surgical techniques, chemoradiation therapy regimens, and pre- and postoperative medications used to treat GC have improved, the median overall survival time of patients with advanced GC remains at ~13 months (2). Tumor heterogeneity has been identified as a factor that negatively affects patient survival and numerous studies have indicated that the involvement of small populations of cancer stem cells (CSCs) within tumor tissues may contribute to this heterogeneity and thus to chemoradiation therapy resistance, local invasion and metastasis to other organs (3-14).

The CSC hypothesis was initially proposed following the prospective identification of leukemia-initiating cells in patients with acute myeloid leukemia (AML) (3,4). The AML studies, which were conducted in immunocompromised mice, revealed a significantly higher leukemic potential in cluster of differentiation (CD)34+CD38- leukemic cells than in CD34⁺CD38⁺ or CD34⁻ cells (3,4). Following the identification of these leukemic stem cells, CSCs or cancer-initiating cells have been identified in various types of solid tumors, including breast, brain, colon, pancreatic, liver and gastric tumors (5-11). Xenotransplantation assays have demonstrated the high capacity of CSCs for self-renewal and, thereby, the likelihood that these cells may regenerate the heterogeneous types of cancer cells that complicate therapeutic approaches (12,13). When characterizing CSCs, the use of human samples, which have usually been resected via surgical procedures, is important to elucidate the mechanisms of chemoresistance, radioresistance, metastasis and recurrence, and to identify novel drug targets against neoplastic diseases with poor prognoses (12,14).

Regarding gastric CSC surface markers, several molecules or combinations of molecules have been reported to indicate cell subsets, including CD44⁺, CD44⁺EpCAM⁺, CD44⁺CD24⁺, and CD90⁺ cells, as well as cells with high aldehyde dehy-

2362

A

Buffe

CD8t

CD1a

CD1h

CD10

CD4

CD4V4 CD14

CD5

CD6

CD7

CD16

CD0a CD18

CD2 CD11b

CD3

CD11c

CD1d

CD11a

		CD20	CD21	CD22	CD23	CD24	CD25	CD26	CD27	CD28	CD29	CD30
	CD19											
	CD31	CD32	CD33	CD34	CD35	CD36	CD37	CD38	CD39	CD40	CD41a	CD41b
	CD42a	CD42b	CD43	CD44	CD45	CD45RA	CD45RB	CD45RO	CD46	CD47	CD48	CD49a
	CD49b	CD49c	CD49d	CD49e	CD50	CD51/61	CD53	CD54	CD55	CD56	CD57	CD58
Case 1	CD59	CD61	CD62E	CD62L	CD62P	CD63	CD64	CD66 (a,c,d,e)	CD66b	CD66f	CD69	CD70
	CD71	CD72	CD73	CD74	CD75	CD77	cd79B	CD80	CD81	CD83	CD84	CD85
	Buffer	CD86	CD87	CD88	CD89	CD90	CD91	CDw93	CD94	CD95	CD97	CD98
	CD99	CD99R	CD100	CD102	CD103	CD105	C106	CD107a	CD107b	CD108	CD109	CD112
	CD114	CD116	CD117	CD118 (LIF R)	CD119	CD120a	CD121a	CD121b	CD122	CD123	CD124	CD126
	CD127	CD128b	CD130	CD134	CD135	CD137	CD138 Ligand	CD138	CD140a	CD140b	CD141	CD142
	CD144	CD146	CD147	CD150	CD151	CD152	CD153	CD154	CD158a	CD158b	CD161	CD162
	CD163	CD164	CD165	CD166	CD171	CD172b	CD177	CD178	CD180	CD181	CD183	CD184
	CD193	CD195	CD196	CD197	CD200	CD205	CD206	CD209	CD220	CD221	CD226	CD227
	CD229	CD231	CD235a	CD243	CD244	CD255	CD268	CD271	CD273	CD274	CD275	CD278
	Buffer	CD279	CD282	CD305	CD309	CD314	CD321	CDw327	CDw328	CDw329	CD335	CD336
	CD337	CD338	CD340	αβTCR	BLTR-1	β2 µglobulin	CLIP	CMRF-44	CMRF-56	EGFR	fMLP R	V §TCR
	Hem. Prog. Cell	HLA-A,B,C	HLA-A2	HLA-DQ	HLA-DR	HLA-DR.DP.DQ	Invariant NKT	Dis-gang GD2	MICA/B	NKB1	SSEA-1	SSEA-4
	TRA-1-60	TRA-1-81	Vβ 23	VB 8								
	mlgM	m lgG1	mlgG2a	mlgG2b	mlgG3							
	CD49f	CD104	CD 120b	CD132	CD201	CD210	CD212	CD267	CD294	CD326	Cut. L Ag	ΙΝΤ β7
	SSEA-3	1										
			_		-					_		
	rigM	rlgG1	rlgG2a	rigG2b	050	000			48.5		007	
	Buffer	CD1a	CD1b	CD1d	CD2	CD3	CD4	CD4V4	CD5	CD6	CD7	CD8a
	Buffer CD8b	CD1a CD9	CD1b CD10	CD1d CD11a	CD11b	CD11c	CD 13	CD14	CD15	CD15s	CD16	CD18
	Buffer CD8b CD19	CD1a CD9 CD20	CD1b CD10 CD21	CD1d CD11a CD22	CD11b CD23	CD11c CD24	CD 13 CD 25	CD14 CD26	CD15 CD27	CD15s CD28	CD16 CD29	CD18 CD30
	Buffer CD8b CD19 CD31	CD1a CD9 CD20 CD32	CD1b CD10 CD21 CD33	CD1d CD11a CD22 CD34	CD11b CD23 CD35	CD11c CD24 CD36	CD13 CD25 CD37	CD14 CD26 CD38	CD15 CD27 CD39	CD15s CD28 CD40	CD16 CD29 CD41a	CD18 CD30 CD41b
	Buffer CD8b CD19	CD1a CD9 CD20 CD32 CD42b	CD1b CD10 CD21	CD1d CD11a CD22 CD34 CD44	CD11b CD23	CD11c CD24 CD36 CD45RA	CD13 CD25 CD37 CD45RB	CD14 CD28 CD38 CD45RO	CD15 CD27 CD39 CD46	CD15s CD28 CD40 CD47	CD16 CD29	CD18 CD30 CD41b CD49a
	Buffer CD8b CD19 CD31 CD42a CD49b	CD1a CD9 CD20 CD32 CD42b CD49c	CD1b CD10 CD21 CD33 CD43 CD49d	CD1d CD11a CD22 CD34 CD44 CD49e	CD11b CD23 CD35 CD45 CD50	CD11c CD24 CD36 CD45RA CD51/61	CD13 CD25 CD37	CD14 CD26 CD38 CD45RO CD54	CD15 CD27 CD39 CD46 CD55	CD15s CD28 CD40	CD16 CD29 CD41a CD48 CD57	CD18 CD30 CD41b CD49a CD58
	Buffer CD8b CD19 CD31 CD42a CD49b CD59	CD1a CD9 CD20 CD32 CD42b CD49c CD61	CD1b CD10 CD21 CD33 CD43 CD49d CD62E	CD1d CD11a CD22 CD34 CD44 CD49e CD62L	CD11b CD23 CD35 CD45 CD50 CD62P	CD11c CD24 CD36 CD45RA CD51/61 CD63	CD 13 CD 25 CD 37 CD 45 RB CD 53 CD 64	CD14 CD26 CD38 CD45RO CD54 CD54 CD66 (a,c,d,e)	CD15 CD27 CD39 CD46 CD55 CD66b	CD15s CD28 CD40 CD47 CD58 CD66f	CD16 CD29 CD41a CD48 CD57 CD69	CD18 CD30 CD41b CD49a CD58 CD70
	Buffer CD8b CD19 CD31 CD42a CD49b CD59 CD71	CD1a CD9 CD20 CD32 CD42b CD42b CD49c CD61 CD72	CD1b CD10 CD21 CD33 CD43 CD49d CD62E CD73	CD1d CD11a CD22 CD34 CD44 CD49e CD62L CD74	CD11b CD23 CD35 CD45 CD50 CD62P CD75	CD11c CD24 CD36 CD45RA CD51/61 CD63 CD77	CD 13 CD 25 CD 37 CD 45RB CD 53 CD 64 cd 79B	CD14 CD28 CD38 CD45RO CD54 CD54 CD68 (a,c,d,e) CD80	CD15 CD27 CD39 CD46 CD55 CD66b CD81	CD15s CD28 CD40 CD47 CD58 CD66f CD83	CD16 CD29 CD41a CD48 CD57 CD69 CD84	CD18 CD30 CD41b CD49a CD58 CD70 CD85
	Buffer CD8b CD19 CD31 CD42a CD49b CD59 CD71 Buffer	CD1a CD9 CD20 CD32 CD42b CD42b CD49c CD61 CD72 CD86	CD1b CD10 CD21 CD33 CD43 CD49d CD62E CD73 CD87	CD1d CD11a CD22 CD34 CD44 CD49e CD62L CD74 CD88	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89	CD11c CD24 CD36 CD45RA CD51/61 CD63 CD77 CD90	CD 13 CD 25 CD 37 CD 45 RB CD 53 CD 64 cd 79 B CD 91	CD14 CD28 CD38 CD45RO CD54 CD66 (a, c, d, e) CD80 CD80 CDw93	CD15 CD27 CD39 CD46 CD55 CD66b CD81 CD94	CD15s CD28 CD40 CD47 CD58 CD66f CD83 CD95	CD16 CD29 CD41a CD48 CD57 CD69 CD84 CD97	CD18 CD30 CD41b CD49a CD58 CD70 CD85 CD98
7	Buffer CD8b CD19 CD31 CD42a CD49b CD59 CD71 Buffer CD99	CD1a CD9 CD20 CD22 CD42b CD42b CD49c CD61 CD72 CD88 CD99R	CD1b CD10 CD21 CD33 CD43 CD49d CD62E CD73 CD87 CD100	CD1d CD11a CD22 CD34 CD44 CD49e CD62L CD74 CD74 CD88 CD102	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89 CD103	CD11c CD24 CD36 CD45RA CD51/61 CD63 CD77 CD90 CD105	CD13 CD25 CD37 CD45RB CD53 CD64 cd79B CD91 C106	CD14 CD28 CD38 CD45RO CD54 CD66 (a,c,d,e) CD80 CD80 CDw93 CD107a	CD15 CD27 CD39 CD46 CD55 CD66b CD81 CD94 CD107b	CD15s CD28 CD40 CD47 CD58 CD66f CD83 CD95 CD108	CD16 CD29 CD41a CD48 CD57 CD69 CD84 CD97 CD109	CD18 CD30 CD41b CD49a CD58 CD70 CD85 CD70 CD85 CD98 CD112
	Buffer C08b C019 C031 C042a C048b C059 C071 Buffer C099 C0114	CD1a CD9 CD20 CD32 CD42b CD42b CD49c CD49c CD51 CD72 CD86 CD99R CD116	CD1b CD10 CD21 CD33 CD43 CD49d CD62E CD73 CD87 CD100 CD117	CD1d CD11a CD22 CD34 CD44 CD49e CD62L CD74 CD88 CD102 CD118 (LF R)	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89 CD103 CD119	CD11c CD24 CD36 CD45RA CD51/61 CD51/61 CD63 CD77 CD90 CD105 CD105 CD120a	CD13 CD25 CD37 CD45RB CD53 CD64 cd79B CD91 C106 CD121a	CD14 CD28 CD38 CD45R0 CD54 CD66 (a,c,d,e) CD80 CDw93 CD107a CD107a	CD15 CD27 CD39 CD48 CD55 CD66b CD81 CD94 CD107b CD122	CD15s CD28 CD40 CD47 CD56 CD66f CD83 CD95 CD108 CD123	CD16 CD29 CD41a CD48 CD57 CD69 CD84 CD97 CD109 CD124	CD18 CD30 CD41b CD49a CD58 CD70 CD85 CD98
	Buffer CD8b CD19 CD31 CD42a CD48b CD59 CD71 Buffer CD99 CD114 CD127	CD1a CD9 CD20 CD32 CD42b CD49e CD49e CD49e CD49e CD49e CD51 CD72 CD88 CD99R CD116 CD128b	CD1b CD10 CD21 CD33 CD43 CD49d CD62E CD73 CD87 CD100	CD1d CD11a CD22 CD34 CD44 CD49e CD62L CD74 CD88 CD102 CD18 (LF R) CD134	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89 CD103 CD119 CD135	CD11c CD24 CD36 CD45RA CD51/61 CD63 CD77 CD90 CD105 CD120a CD137	CD13 CD25 CD37 CD45RB CD53 CD64 cd79B CD91 C106	CD14 CD28 CD38 CD45RO CD54 CD66 (a,c,d,e) CD89 CDx93 CD107a CD121b CD138	CD15 CD27 CD39 CD46 CD55 CD66b CD81 CD94 CD107b CD122 CD140a	CD15s CD28 CD40 CD47 CD56 CD66f CD83 CD95 CD108 CD123 CD140b	CD16 CD29 CD41a CD48 CD57 CD69 CD84 CD97 CD109 CD124 CD141	CD18 CD30 CD41b CD49a CD58 CD70 CD85 CD98 CD112 CD126 CD142
	Buffer C08b C019 C031 CD49b C059 C071 Buffer C099 C0114 C0127 C0127	CD1a CD9 CD20 CD42b CD42b CD49e CD49e CD51 CD72 CD88 CD99R CD116 CD128b CD146	CD1b CD10 CD21 CD33 CD43 CD43 CD43 CD49d CD62E CD73 CD87 CD100 CD117 CD130 CD147	CD1d CD11a CD22 CD34 CD44 CD49e CD62L CD74 CD88 CD102 CD118 (LF R) CD134 CD150	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89 CD103 CD119 CD135 CD151	CD11c CD24 CD36 CD45RA CD51/81 CD63 CD77 CD90 CD105 CD120a CD137 CD152	CD13 CD25 CD37 CD45RB CD53 CD64 cd79B CD91 C106 CD121a CD138 Ligand CD153	CD14 CD28 CD38 CD45RO CD54 CD66 (a,c,d,e) CD60 CDx63 CD107a CD107a CD121b CD128 CD154	CD15 CD27 CD39 CD46 CD55 CD66b CD81 CD84 CD107b CD107b CD122 CD140a CD158a	CD15s CD28 CD40 CD47 CD56 CD66f CD83 CD95 CD108 CD123 CD140b CD158b	CD16 CD29 CD41a CD48 CD57 CD69 CD84 CD97 CD109 CD124 CD141 CD161	CD18 CD30 CD41b CD49a CD58 CD70 CD85 CD98 CD112 CD126 CD142 CD162
Case Z	Buffer CD8b CD19 CD31 CD42a CD48b CD59 CD71 Buffer CD99 CD114 CD127	CD1a CD9 CD20 CD32 CD42b CD49e CD49e CD49e CD49e CD49e CD51 CD72 CD88 CD99R CD116 CD128b	CD1b CD10 CD21 CD33 CD43 CD49d CD62E CD73 CD87 CD100 CD117 CD130	CD1d CD11a CD22 CD34 CD44 CD49e CD62L CD74 CD88 CD102 CD18 (LF R) CD134	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89 CD103 CD119 CD135	CD11c CD24 CD36 CD45RA CD51/61 CD63 CD77 CD90 CD105 CD120a CD137	CD 13 CD 25 CD 37 CD 45RB CD 53 CD 64 cd 79B CD 91 C106 CD 121a CD 138 Ligand	CD14 CD28 CD38 CD45RO CD54 CD66 (a,c,d,e) CD89 CDx93 CD107a CD121b CD138	CD15 CD27 CD39 CD46 CD55 CD66b CD81 CD94 CD107b CD122 CD140a	CD15s CD28 CD40 CD47 CD56 CD66f CD83 CD95 CD108 CD123 CD140b	CD16 CD29 CD41a CD48 CD57 CD69 CD84 CD97 CD109 CD124 CD141	CD18 CD30 CD41b CD49a CD58 CD70 CD85 CD98 CD112 CD126 CD142 CD162 CD184
	Buffer CD8b CD19 CD31 CD48b CD59 CD71 Buffer CD99 CD114 CD127 CD148 CD143	CD1a CD9 CD20 CD32 CD42b CD42b CD42b CD61 CD72 CD66 CD72 CD66 CD166 CD128b CD146 CD128b CD146 CD195	CD1b CD10 CD21 CD33 CD43 CD43 CD43 CD43 CD43 CD43 CD73 CD73 CD73 CD73 CD17 CD100 CD147 CD165 CD196	CD1d CD11a CD22 CD34 CD44 CD49e CD62L CD74 CD88 CD102 CD18 (LF R) CD134 CD150 CD166 CD197	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89 CD103 CD119 CD135 CD151 CD151 CD171 CD200	CD11c CD24 CD36 CD45RA CD51/81 CD577 CD83 CD177 CD165 CD120a CD152 CD152 CD152 CD152 CD152	CD 13 CD 25 CD 37 CD 45RB CD 53 CD 64 ed 79B CD 91 CD 91 CD 91 CD 138 CD 121a CD 153 CD 153 CD 153 CD 1277 CD 206	CD14 CD26 CD38 CD45RO CD54 CD66 (a,c,d,e) CD80 CDw93 CD107a CD121b CD121b CD124 CD124 CD178 CD178 CD209	CD15 CD27 CD39 CD46 CD55 CD665 CD64 CD64 CD64 CD1675 CD122 CD140a CD158a CD180 CD180 CD180	CD15s CD28 CD40 CD47 CD56 CD66f CD83 CD95 CD108 CD123 CD140b CD158b CD181 CD221	CD16 CD29 CD41a CD48 CD57 CD69 CD84 CD97 CD109 CD124 CD161 CD161 CD163 CD226	CD18 CD30 CD41b CD49a CD58 CD70 CD85 CD98 CD112 CD126 CD142 CD162 CD162 CD184 CD227
	Buffer CD8b CD19 CD31 CD42a CD48b CD59 CD71 Buffer CD99 CD114 CD127 CD144 CD127 CD144	CD1a CD9 CD20 CD32 CD42b CD42c CD61 CD72 CD88 CD98R CD116 CD128b CD144	CD1b CD10 CD21 CD33 CD43 CD49d CD62E CD73 CD87 CD100 CD117 CD100 CD117 CD100 CD147 CD165	CD1d CD11a CD22 CD34 CD49 CD62L CD74 CD62L CD74 CD88 CD102 CD18 (LF R) CD134 CD150 CD150	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89 CD103 CD103 CD119 CD135 CD151 CD171	CD11c CD24 CD36 CD45RA CD51/61 CD63 CD77 CD90 CD105 CD120a CD137 CD152 CD152 CD152	CD13 CD25 CD37 CD45RB CD53 CD64 cd798 CD91 C106 CD121a CD138 Ligand CD153 CD177	CD14 CD28 CD38 CD45RO CD54 CD66 (a, c, d, e) CD80 CD107a CD107a CD121b CD138 CD154 CD178 CD154 CD178 CD174 CD178	CD15 CD27 CD39 CD46 CD55 CD66b CD81 CD84 CD107b CD122 CD140a CD158a CD188a	CD15s CD28 CD40 CD47 CD56 CD66f CD83 CD95 CD108 CD123 CD140b CD158b CD181	CD16 CD29 CD41a CD48 CD57 CD69 CD84 CD97 CD109 CD124 CD141 CD161 CD183	CD18 CD30 CD41b CD49a CD58 CD70 CD85 CD98 CD112 CD126 CD142 CD162 CD162 CD184 CD227
	Buffer CD8b CD19 CD31 CD42a CD48b CD59 CD71 Buffer CD99 CD114 CD127 CD143 CD144 CD127 CD143 CD144 CD163 CD183 CD228 Buffer	CD1a CD9 CD20 CD32 CD42b CD42e CD81 CD72 CD88 CD99R CD116 CD128b CD146 CD144 CD145 CD144 CD195 CD279	CD1b CD10 CD21 CD33 CD49 CD62E CD73 CD87 CD100 CD117 CD100 CD117 CD100 CD117 CD165 CD196 CD196 CD252a CD282	CD1d CD11a CD22 CD34 CD49 CD62L CD74 CD62L CD74 CD88 CD102 CD18 (LF R) CD134 CD150 CD166 CD197 CD197 CD243 CD305	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89 CD103 CD19 CD135 CD151 CD151 CD200 CD244 CD309	CD11c CD24 CD36 CD45RA CD51/61 CD63 CD77 CD105 CD105 CD120 CD137 CD152 CD152 CD152 CD152 CD152 CD255 CD255 CD2514	CD13 CD25 CD37 CD45RB CD53 CD64 cd798 CD91 C106 CD121a CD138 Ligand CD153 CD153 CD153 CD177 CD206 CD2288 CD321	CD14 CD28 CD33 CD45RO CD54 CD66 (a.c.d.e) CD80 CD107 CD1215 CD138 CD178 CD154 CD178 CD178 CD178 CD209 CD271 CD2921	CD15 CD27 CD39 CD46 CD55 CD66b CD61 CD64 CD167b CD122 CD140a CD158a CD158a CD183 CD202 CD273 CD273	CD15s CD28 CD40 CD47 CD56 CD667 CD83 CD95 CD108 CD123 CD140b CD158b CD168b CD158b CD181 CD221 CD274 CDw329	CD16 CD29 CD41a CD57 CD69 CD94 CD97 CD109 CD124 CD141 CD161 CD161 CD183 CD228 CD275 CD35	CD18 CD30 CD41b CD49a CD58 CD70 CD85 CD98 CD112 CD128 CD128 CD142 CD164 CD164 CD127 CD277 CD278 CD336
	Buffer CD8b CD19 CD31 CD42a CD49b CD59 CD71 Buffer CD99 CD114 CD127 CD144 CD143 CD143 CD183 CD229 Buffer CD337	CD1a CD9 CD20 CD42b CD42b CD42b CD42b CD42b CD42b CD51 CD72 CD88 CD146 CD128b CD146 CD128b CD146 CD195 CD231 CD231 CD231 CD238	CD1b CD10 CD21 CD33 CD43 CD434 CD62E CD73 CD87 CD100 CD117 CD100 CD147 CD165 CD198 CD198 CD252 CD254 CD254 CD254 CD254	CD1d CD11a CD22 CD34 CD44 CD49e CD62L CD74 CD88 CD102 CD18 (LF R) CD134 CD150 CD150 CD166 CD197 CD243 CD305 αβTCR	CD11b CD23 CD35 CD50 CD50 CD62P CD75 CD75 CD103 CD119 CD135 CD151 CD171 CD200 CD244 CD309 BLTR-1	СD11c CD24 CD26 CD45RA CD51/61 CD63 CD77 CD60 CD105 CD120a CD152 CD152 CD152 CD152 CD152 CD255 CD255 CD255 CD254 CD255	CD13 CD25 CD37 CD45RB CD53 CD64 ed798 CD91 C106 CD121a CD138 Ligand CD153 CD153 CD153 CD153 CD157 CD208 CD228 CD228 CD228 CD228 CD286 CD228 CD286 CD286 CD286 CD285 CD296 CD295 CD297 CD297 CD297 CD297 CD297 CD45 CD91 CD91 CD91 CD91 CD91 CD91 CD91 CD91	CD14 CD28 CD38 CD45RO CD54 CD66 (a,c,d,e) CD80 CDw93 CD107a CD121b CD138 CD154 CD154 CD154 CD178 CD209 CD271 CDw927 CMRF-44	CD15 CD27 CD39 CD46 CD55 CD66b CD64 CD64 CD107b CD102 CD107b CD122 CD140a CD158a CD180 CD158a CD180 CD220 CD273 CDx328 CMRF-58	CD15s CD28 CD40 CD47 CD58 CD66f CD83 CD955 CD108 CD123 CD108 CD123 CD140b CD181 CD221 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD275 CD108 CD275 CD27	CD16 CD29 CD41a CD48 CD57 CD69 CD97 CD124 CD124 CD124 CD124 CD141 CD183 CD228 CD228 CD228 CD275 CD335 MLP R	СD18 CD30 CD41b CD49a CD58 CD70 CD85 CD95 CD95 CD95 CD122 CD126 CD142 CD142 CD162 CD184 CD277 CD278 CD338 убТСR
	Buffer CD8b CD19 CD31 CD48b CD59 CD71 Buffer CD99 CD114 CD163 CD163 CD229 Buffer CD183 CD237 Hem. Prog. Cell	CD1a CD9 CD20 CD42b CD42b CD42b CD42b CD42b CD52 CD58 CD98R CD128 CD128 CD148 CD148 CD148 CD146 CD128 CD148 CD148 CD148 CD148 CD148 CD148 CD14 CD279 CD23 CD279 CD23 CD279 CD26 CD26 CD26 CD26 CD26 CD26 CD26 CD26	CD1b CD10 CD21 CD33 CD43 CD49d CD62E CD73 CD87 CD100 CD17 CD130 CD147 CD165 CD196 CD196 CD235a CD282 CD282 CD282	CD1d CD11a CD22 CD34 CD44 CD49e CD62L CD74 CD88 CD102 CD188 CD102 CD184 CD150 CD134 CD150 CD166 CD197 CD243 CD305	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89 CD103 CD19 CD135 CD151 CD151 CD200 CD244 CD309	CD11c CD24 CD36 CD45RA CD51/61 CD63 CD77 CD105 CD105 CD120 CD137 CD152 CD152 CD152 CD152 CD152 CD255 CD255 CD2514	CD13 CD25 CD37 CD45RB CD53 CD64 cd798 CD91 C106 CD121a CD138 Ligand CD153 CD153 CD153 CD177 CD206 CD2288 CD321	CD14 CD28 CD33 CD45RO CD54 CD66 (a.c.d.e) CD80 CD107 CD1215 CD138 CD178 CD154 CD178 CD178 CD178 CD209 CD271 CD2921	CD15 CD27 CD39 CD46 CD55 CD66b CD61 CD64 CD167b CD122 CD140a CD158a CD158a CD183 CD202 CD273 CD273	CD15s CD28 CD40 CD47 CD56 CD667 CD83 CD95 CD108 CD123 CD140b CD158b CD168b CD158b CD181 CD221 CD274 CDw329	CD16 CD29 CD41a CD57 CD69 CD94 CD97 CD109 CD124 CD141 CD161 CD161 CD183 CD228 CD275 CD35	СD18 CD30 CD41b CD49a CD58 CD70 CD85 CD95 CD95 CD126 CD126 CD142 CD162 CD162 CD184 CD277 CD278 CD336 y5TCR
	Buffer CD8b CD19 CD31 CD42a CD48b CD59 CD71 Buffer C099 CD114 CD127 CD183 CD228 Buffer CU337 TRA-1-60	CD1a CD9 CD20 CD42b CD42b CD42b CD42b CD51 CD72 CD86 CD164 CD164 CD164 CD164 CD164 CD195 CD279 CD338 HLAAEC TRA-1-81	СD1b CD10 CD21 CD33 CD43 CD43 CD43 CD65 CD106 CD106 CD147 CD165 CD186 CD253a CD282 CD282 CD2840 HLA-42 VB 23	СD1d CD11a CD22 CD34 CD49 CD49 CD62L CD74 CD88 CD102 CD174 CD134 CD134 CD150 CD150 CD166 CD197 CD233 CD305 @JTCR HLADQ V§ 8	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89 CD103 CD119 CD135 CD151 CD270 CD244 CD309 BLTR-1 HLA-DR	СD11c CD24 CD26 CD45RA CD51/61 CD63 CD77 CD60 CD105 CD120a CD152 CD152 CD152 CD152 CD152 CD255 CD255 CD255 CD254 CD255	CD13 CD25 CD37 CD45RB CD53 CD64 ed798 CD91 C106 CD121a CD138 Ligand CD153 CD153 CD153 CD153 CD157 CD208 CD228 CD228 CD228 CD228 CD286 CD228 CD286 CD286 CD286 CD285 CD296 CD295 CD297 CD297 CD297 CD297 CD297 CD45 CD91 CD91 CD91 CD91 CD91 CD91 CD91 CD91	CD14 CD28 CD38 CD45RO CD54 CD66 (a,c,d,e) CD80 CDw93 CD107a CD121b CD138 CD154 CD154 CD154 CD178 CD209 CD271 CDw927 CMRF-44	CD15 CD27 CD39 CD46 CD55 CD66b CD64 CD64 CD107b CD102 CD107b CD122 CD140a CD158a CD180 CD158a CD180 CD220 CD273 CDx328 CMRF-58	CD15s CD28 CD40 CD47 CD58 CD66f CD83 CD955 CD108 CD123 CD108 CD123 CD140b CD181 CD221 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD275 CD108 CD275 CD27	CD16 CD29 CD41a CD48 CD57 CD69 CD97 CD124 CD124 CD124 CD124 CD141 CD183 CD228 CD228 CD228 CD275 CD335 MLP R	СD18 CD30 CD41b CD49a CD58 CD70 CD85 CD95 CD95 CD126 CD126 CD142 CD162 CD162 CD184 CD277 CD278 CD336 y5TCR
	Buffer CD8b CD19 CD31 CD42a CD49b CD59 CD71 Buffer CD99 CD114 CD127 CD143 CD144 CD128 CD183 CD299 Buffer CD337 Hem. Prog. Cell TRA-1.80 mtgM	CD1a CD9 CD20 CD42b CD42b CD42b CD42b CD42b CD72 CD98 CD146 CD128b CD146 CD128b CD144 CD195 CD231 CD231 CD238 HLAAB.C TRA-138 mgG1	CD1b CD10 CD21 CD43 CD43 CD49d CD62E CD73 CD87 CD100 CD117 CD100 CD117 CD100 CD147 CD100 CD147 CD165 CD198 CD282 CD255a CD285 CD282 CD240 CD285a CD282 CD240 CD285a CD282 CD285 CD282 CD285 CD285 CD285 CD285 CD285 CD285 CD100 CD10 CD287 CD100 CD21 CD21 CD21 CD21 CD21 CD21 CD21 CD21	СD1d CD11a CD22 CD34 CD44 CD49e CD62L CD74 CD88 CD102 CD186 (LF R) CD134 CD150 CD243 CD355	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD62P CD75 CD19 CD135 CD19 CD135 CD171 CD200 CD244 CD309 BLTR-1 HLA-DR mlgG3	CD11c CD24 CD36 CD45RA CD51/81 CD83 CD77 CD90 CD105 CD120a CD152 CD152 CD152 CD152 CD152 CD152 CD152 CD255 CD255 CD255 CD254 HLADR,DP,DQ	CD 13 CD 25 CD 37 CD 45RB CD 53 CD 64 e d 79B CD 91 CD 64 CD 121a CD 138 Ligand CD 153 CD 177 CD 206 CD 226 CD 227 CLIP	CD14 CD28 CD38 CD45RO CD54 CD66 (a,c,d,e) CD80 CDw93 CD17a CD12b C	CD15 CD27 CD39 CD46 CD55 CD66b CD81 CD94 CD107b CD102 CD102 CD140a CD168a CD168a CD168a CD168a CD168a CD168a CD168a CD220 CD273 CDx28 CDx28 CDx27 CDx28 CDx5 CDx6 CD27 CDx6 CD27 CD27 CD27 CD27 CD27 CD27 CD27 CD27	CD156 CD28 CD47 CD56 CD667 CD687 CD687 CD687 CD687 CD123 CD1406 CD123 CD1406 CD123 CD1406 CD123 CD1406 CD123 CD1406 CD123 CD1406 CD123 CD1406 CD123 CD1406 CD123 CD140 CD123 CD140 CD123 CD140 CD123 CD140 CD123 CD140 CD25 CD140 CD25 CD26 CD26 CD26 CD26 CD26 CD26 CD26 CD26	CD16 CD29 CD41a CD48 CD57 CD69 CD7 CD69 CD7 CD104 CD141 CD141 CD161 CD128 CD228 CD228 CD275 CD235 MLP R SSEA-1	CD18 CD30 CD41b CD49a CD58 CD70 CD85 CD126 CD126 CD126 CD142 CD162 CD142 CD162 CD142 CD162 CD184 CD278 CD338 Y&TCR SSEA-4
	Buffer CD8b CD19 CD31 CD42a CD48b CD59 CD71 Buffer C099 CD114 CD127 CD183 CD228 Buffer CU337 TRA-1-60	CD1a CD9 CD20 CD42b CD42b CD42b CD42b CD51 CD72 CD86 CD164 CD164 CD164 CD164 CD164 CD195 CD279 CD338 HLAAEC TRA-1-81	СD1b CD10 CD21 CD33 CD43 CD43 CD43 CD65 CD106 CD106 CD147 CD165 CD186 CD253a CD282 CD282 CD2840 HLA-42 VB 23	СD1d CD11a CD22 CD34 CD49 CD49 CD62L CD74 CD88 CD102 CD174 CD134 CD134 CD150 CD150 CD166 CD197 CD233 CD305 @JTCR HLADQ V§ 8	CD11b CD23 CD35 CD45 CD50 CD62P CD75 CD89 CD103 CD119 CD135 CD151 CD270 CD244 CD309 BLTR-1 HLA-DR	СD11c CD24 CD26 CD45RA CD51/61 CD63 CD77 CD60 CD105 CD120a CD152 CD152 CD152 CD152 CD152 CD255 CD255 CD255 CD254 CD255	CD13 CD25 CD37 CD45RB CD53 CD64 ed798 CD91 C106 CD121a CD138 Ligand CD153 CD153 CD153 CD153 CD157 CD208 CD228 CD228 CD228 CD228 CD286 CD228 CD286 CD286 CD286 CD285 CD296 CD295 CD297 CD297 CD297 CD297 CD297 CD45 CD91 CD91 CD91 CD91 CD91 CD91 CD91 CD91	CD14 CD28 CD38 CD45RO CD54 CD66 (a,c,d,e) CD80 CDw93 CD107a CD121b CD138 CD154 CD154 CD154 CD178 CD209 CD271 CDw927 CMRF-44	CD15 CD27 CD39 CD46 CD55 CD66b CD64 CD64 CD107b CD102 CD107b CD122 CD140a CD158a CD180 CD158a CD180 CD220 CD273 CDx328 CMRF-58	CD15s CD28 CD40 CD47 CD58 CD66f CD83 CD955 CD108 CD123 CD108 CD123 CD140b CD181 CD221 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD274 CD275 CD108 CD275 CD27	CD16 CD29 CD41a CD48 CD57 CD69 CD97 CD124 CD124 CD124 CD124 CD141 CD183 CD228 CD228 CD228 CD275 CD335 MLP R	СD18 CD30 CD41b CD49a CD58 CD70 CD85 CD95 CD95 CD95 CD122 CD126 CD142 CD142 CD162 CD184 CD277 CD278 CD338 убТСR




Figure 1. Surface marker screening of surgical specimen-derived xenografts. (A) Heat map of surface marker screening. (B) Multicolor flow cytometric analysis of candidate surface markers. (C) Five representative cases of flow cytometric analyses using CD26 and CD44. CD, cluster of differentiation.

drogenase activity (11,15-20). However, the hyaluronic acid receptor, CD44, cannot be used to specifically detect gastric CSCs, even when combined with CD133 (21). In the present study, the cell surface markers expressed on surgically resected GC cells were comprehensively profiled in combination with a xenograft study in immunodeficient mice to identify novel




Figure 2. Sphere formation of CD26/CD44 expression-defined subsets.(A) GC cell line morphologies in adherent or spherical states. (B) Representative increased CD26 expression data following sphere formation. (C) CD26 expression following sphere formation in four GC cell lines. CD, cluster of differentiation; GC, gastric cancer.

markers for the detection of gastric CSCs. This approach facilitated the identification of the combination of CD44 and CD26 as a useful marker of cancer stem cell properties.

Materials and methods

Cancer cells. Fresh surgically resected well-differentiated GC specimens were obtained at Osaka University Medical Hospital (Osaka, Japan) between 2011 and 2012 and written informed consent was obtained from all patients. This study was approved by the ethics committee of Osaka University (Osaka, Japan). The GC cell lines (MKN7, MKN28, MKN45 and AZ521, were provided by the Department of Gastroenterological Surgery, Osaka University) were cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific Inc., Waltham, MA, USA) and an antibiotic/antimycotic solution (Sigma-Aldrich). To facilitate sphere formation, the cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 medium supplemented with 20 ng/ml of recombinant human epidermal growth factor (EGF; Promega Corporation, Madison, WI, USA) and 10 ng/ml of basic fibroblast growth factor (FGF; PeproTech Inc., Rocky Hill, NJ, USA) in 96-well plates, six-well plates, or 100-mm dishes with Ultra-Low Attachment surfaces (Corning Inc., Corning, NY, USA).

Antibody arrays and flow cytometric studies. A Lyoplate® assay (BD Biosciences, San Jose, CA, USA) was used to screen surface markers, and was equipped with antibodies against 242 human cell surface markers, (mouse anti-human monoclonal antibodies: CD1a, CD1b, CD1d, CD2, CD3, CD4, CD4v4, CD5, CD6, CD7, CD8a, CD8b, CD9, CD10, CD11a, CD11b, CD11c, CD13, CD14, CD15, CD15s, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41a, CD41b, CD42a, CD42b, CD43, CD44, CD45, CD45RA, CD45RB, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD50, CD51/61, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD61, CD62E, CD62L, CD62P, CD63, CD64, CD66a, -c, -d, -e), CD66b, CD66f, CD69, CD70, CD71, CD72, CD73, CD74, CD75, CD77, CD79b, CD80, CD81, CD83, CD84, CD85, CD86, CD87, CD88, CD89, CD90, CD91, CDw93, CD94, CD95, CD97, CD98, CD99, CD99R, CD100, CD102, CD103, CD105, CD106, CD107a, CD107b, CD108, CD109, CD112,




Figure 3. Tumorigenicity of CD26/CD44 expression-defined subsets. (A) Excised tumors formed following the injection of cell subsets. (B) Flow cytometric tumor re-analysis. (C) Histological tumor analysis (hematoxylin-eosin staining). CD, cluster of differentiation.

CD114, CD116, CD117, CD118, CD119, CD120a, CD121a, CD121b, CD122, CD123, CD124, CD126, CD127, CD128b, CD130, CD134, CD135, CD137, CD137 ligand, CD138, CD140a, CD140b, CD141, CD142, CD144, CD146, CD147, CD150, CD151, CD152, CD153, CD154, CD158a, CD158b, CD161, CD162, CD163, CD164, CD165, CD166, CD171, CD279, CD282, CD305, CD309, CD314, CD321, CDw327, CDw328, CDw329, CD335, CD336, CD337, CD338, CD304, $\alpha\beta$ T CR, β 2-microglobulin, human leukotriene B4 receptor-1, CLIP, CMRF-44, CMRF-56, epidermal growth factor receptor, fMLP receptor, $\gamma\delta$ TCR, hybrid protein complex, human leukocyte antigen (HLA)-A, -B, -C, HLA-A2, HLA- DQ, HLA- DR, HLA-DR, -DP, -DQ, Invariant NK T, Disialoganglioside GD2, MIC A/B, NKB1, stage-specific embryonic antigen (SSEA)-1, SSEA- 4, TRA-1-60, TRA-1-81, Vβ 23, Vβ 8 and CD326; rat anti-human monoclonal antibodies: CD49f, CD104, CD120b, CD132, CD201, CD210, CD212, CD267, CD294, SSEA4, cutaneous lymph antigen and Integrin β7), according to the manufacturer's instructions. Briefly, to evaluate the cell lines, the cells were detached from the culture dishes (Iwaki & Co., Ltd. Tokyo, Japan) using the AccutaseTM Cell Detachment Solution (BD Biosciences) and were washed with Dulbecco's phosphate-buffered saline (Wako Pure Chemical Industries, Ltd., Osaka, Japan). To evaluate fresh surgical specimens or xenografts, the tumor tissues were dissected into small sections, and digested with collagenase H (Roche Diagnostics, Basel, Switzerland) and DNase I (Worthington Biochemical Corporation, Lakewood, NJ, USA) for 1 h at 37°C. Next, the digested tissues were filtered through a 100- μ m filter, layered over Ficoll 1077 (GE Healthcare Life Sciences, Pittsburgh, PA, USA) and centrifuged to remove dead cells and debris. The resuspended cells were treated with TruStain fcX[™] monoclonal rat anti-mouse CD16/32 antibody (BioLegend, Inc., San Diego, CA, USA) and a human FcR blocking reagent (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) to block the Fc receptors, followed by staining with antibodies against CD26-phycoerythrin (PE), CD24, CD44, CD47 and CD147 (BD Biosciences); CD26-PE-Cyanin 5 (BioLegend); and CD15 (Beckman-Coulter, Indianapolis, IN, USA) for 30 min to evaluate the surface expression levels. To exclude mouse cells, the cells were first incubated with a biotinylated anti-mouse Lineage Panel (monoclonal rat TER-119, CD11b, Gr-1, CD45R/B220 and hamster CD3e antibodies), monoclonal rat anti-mouse H-2Kd and CD31 antibodies (all purchased from BioLegend), followed by streptavidin-conjugated Pacific Blue (Invitrogen Life Technologies, Carlsbad, CA, USA). Human GC cell lines were cultured in RPMI-1640 medium supplemented with 10% FBS with or without 5FU. For sphere formation, the cell lines were cultured for 7 d in Ultra-low Attachment dishes (Corning Inc.) at a density of $\leq 5 \times 10^6$ cells/dish. Briefly, the cells were collected and washed to remove serum and then suspended in serum-free DMEM/F12 supplemented with 20 ng/ml of human recombinant EGF, 10 ng/ml human recombinant basic FGF, 2% B27 supplement without vitamin A and 1% N2 supplement (Invitrogen Life Technologies). The spheres with a diameter of >50 μ m were counted and collected via gentle centrifugation with a pipette.

Tumorigenicity. A total of 24 four- to six-week-old female non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice (CLEA Japan Inc., Tokyo, Japan) were used as subcutaneous xenograft models under specific pathogen-free conditions. The tumor volumes were calculated using the following formula: Tumor volume = (longest diameter) x (shortest diameter)² x 0.5. This study was approved by the Animal Experiments Committee of Osaka University.

Statistical analysis. Data are expressed as the mean \pm standard deviation. Continuous variables were compared using the Student's t-test. Statistical analyses were performed using JMP statistical software, version 9.0 (SAS Institute Inc., Cary, NC, USA).

Results

Antibody-based array and flow cytometry. Two surgically resected GC xenografts were assessed for surface marker expression via flow cytometry (Fig. 1A). The antibody-based array study indicated that 27 of the 242 evaluated surface markers were expressed in the two xenografts. The subsequent multicolor flow cytometric analysis confirmed that among these markers, CD15, CD24, CD26, CD44, CD47 and CD147 extended the expression profiling from the negative to the positive range and further revealed that the combination of CD26 and CD44 may be used to fractionate the GC xenograft cells




Figure 4. Chemoresistant subsets according to CD26/CD44 expression. (A) Representative flow cytometric data following exposure to chemotherapeutic agents. Percentages of (B) CD26⁺ and (C) CD44⁺ cells following exposure to 5FU. CD, cluster of differentiation; 5FU, 5-fluorouracil.

into three subsets (Fig. 1B). The confirmation study indicated that five of the flow cytometrically analyzed cases were consistently fractionated into at least three subsets according to the combined CD26 and CD44 expression statuses (Fig. 1C).

Sphere formation induces CD26⁺ cells. Cell culture conditions suitable for sphere formation have been reported to support stem-like cell maintenance and, presumably, to induce at least partial CSC induction, which consequently enriches CSC cell populations (6,22). Four GC cell lines (MKN7, MKN28, MKN45 and AZ521) were used in a sphere formation assay. Distinct spheres were formed after culturing the cell lines in serum-free and unattached conditions (Fig. 2A). Flow cytometric analysis of the adherent cells and spheres revealed that sphere formation enriched the CD26⁺ cell subset in three out of four of the examined cell lines (Fig. 2B and C).

CD26⁺CD44⁺ cells exhibit high tumorigenic potential. The tumorigenicity of each CD26- and CD44-defined subset was

assessed. Cells from a surgically obtained specimen-derived GC xenograft (Case 1) were sorted via fluorescence-activated cell sorting into three subsets, CD26+CD44+, CD26+CD44-, and CD26⁻CD44⁻, and were then subcutaneously injected into NOD/SCID mice. The largest and most frequent tumor formations were obtained with the CD26⁺CD44⁺ subset. The subset formed relatively small tumors; however, the frequency of tumor formation was higher with CD26⁺CD44⁻ subset than with the CD26 CD44 subset (Fig. 3A). Flow cytometric analysis of the formed tumors revealed the recapitulation of three subsets similar to those in the original xenograft (Figs. 1C and 3B). The histological characteristics of the formed tumors were similar to those of the xenograft prior to sorting and of the original patient sample (Fig. 3C).

Roles of CD26 and CD44 in chemoresistance. Chemoresistance is a clinically important feature of CSCs. GC cells cultured in the presence of 5FU exhibited increased frequencies (%) of CD26⁺ cells in a 5FU dose-dependent manner (Fig. 4A and B). In contrast to CD26, the frequencies of CD44⁺ cells decreased following 5FU exposure (Fig. 4C). The MKN28 and AZ521 cells were completely CD44⁻ prior to and following 5FU exposure, as determined via flow cytometry (data not shown).

Discussion

Monoclonal antibodies have been used to identify and characterize cell surface molecules, and similar techniques have been utilized in various research fields, including immunology, hematopoietic stem cell biology and cancer stem cell biology (23). To date, >350 cell surface molecules are numbered according to CD nomenclature; however, a recent bioinformatics study reported that 3,702 transmembrane proteins are expressed on the surfaces of human cells (24).

To the best of our knowledge, there have been no comprehensive reports of cell surface molecule expression evaluations in surgically resected primary GC using >242 molecules, as evaluated in the current study. Among the screened surface markers in this study, the combination of CD26 and CD44 was shown to be capable of dividing GC xenograft cells into three to four subsets via flow cytometry (Fig. 1B and C). In a xenotransplantation experiment, similar tumorigenic efficiencies were demonstrated in the CD26+CD44+ and CD26⁺CD44⁻ cells, in contrast to the low tumorigenicity of the CD26⁻CD44⁻ subset (Fig. 3A and B). These data indicate that the insufficiency of CD44 as a CSC marker may be improved by the complementary use of CD26 as a co-marker.

As a result of the CSC hypothesis, cancer cells within whole tumor tissues have been classified into two major groups, the tumorigenic and non-tumorigenic CSCs (non-CSCs). However, recently, tumorigenic cell heterogeneity with respect to clonal dominancy and chemoresistance was identified using of clonal tracking techniques based on lentiviral insertion sites (25,26). Kreso et al (25) reported five types of clones within colorectal cancer xenografts. In contrast to actively proliferating clones, the slow-growing cell types supposedly became dominant following chemotherapy (25). In the present study, CD26+CD44+ cells formed relatively larger tumors when compared with CD26⁺CD44⁻ cells (Fig. 3A). This observation indicates that CD26⁺CD44⁺ cells underwent rapid proliferation, unlike the CD26⁺CD44⁻ cells. However, following 5FU exposure, the frequencies of CD44⁺ cells decreased significantly in vitro, whereas the frequencies of CD26⁺ cells increased (Fig. 4). These results indicate that although CD26⁺CD44⁺ cells and CD26⁺CD44⁻ cells may initiate tumor growth and regenerate histologically and phenotypically similar tumors (Fig. 3B and C), the cell subsets may differ with respect to proliferative activity and chemotherapeutic sensitivity. Consequently, the role of CSC in therapeutic resistance remains clinically important. The identification of a therapy-resistant CSC subset may accelerate the process of CSC hypothesis-based novel therapy development.

Acknowledgements

The authors would like to thank Miyuki Ozaki and Yuko Noguchi for their technical support. The current study was partly supported by a Core Research Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan (to M.K., H.I. and M.M.; grant nos.; 26670604, 23390199 and 21229015); a Grant-in-Aid from the Third Term Comprehensive 10-year Strategy for Cancer Control of the Ministry of Health, Labor, and Welfare in Japan (to H.I. and M.M.; grant no. H26-018); a grant from the Kobayashi Cancer Research Foundation (to H.I.; grant no. H24); a grant from the Princess Takamatsu Cancer Research Fund, Japan (to H.I.; grant no. H22); and a grant from the SENSHIN Medical Research Foundation (to H.I.; grant no. H25).

The authors received partial support from Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan), Yakult Honsha Co., Ltd. (Tokyo, Japan), and Takeda Pharmaceutical Co., Ltd (Osaka, Japan).

References

- 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
- 2. Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
- 3. Lapidot T, Sirard C, Vormoor J, et al: A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367: 645-648, 1994.
- 4. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
- 5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. 6. Singh SK, Hawkins C, Clarke ID, *et al*: Identification of human
- brain tumor initiating cells. Nature 432: 396-401, 2004.
- 7. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 445: 106-110, 2007.
- 8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007
- 9. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.
- 10. Haraguchi N, Ishii H, Mimori K, et al: CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 120: 3326-3339, 2010.
- 11. Takaishi S, Okumura T, Tu S, et al: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27: 1006-1020, 2009.

- Clarke MF, Dick JE, Dirks PB, *et al*: Cancer stem cells perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
- O'Brien CA, Kreso A and Jamieson CH: Cancer stem cells and self-renewal. Clin Cancer Res 16: 3113-3120, 2010.
- Medema JP: Cancer stem cells: the challenges ahead. Nat Cell Biol 15: 338-344, 2013.
- Fukuda K, Saikawa Y, Ohashi M, *et al*: Tumor initiating potential of side population cells in human gastric cancer. Int J Oncol 34: 1201-1207, 2009.
- Han ME, Jeon TY, Hwang SH, *et al*: Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci 68: 3589-3605, 2011.
- Zhang C, Li C, He F, Cai Y and Yang H: Identification of CD44⁺CD24⁺ gastric cancer stem cells. J Cancer Res Clin Oncol 137: 1679-1686, 2011.
- 18. Jiang J, Zhang Y, Chuai S, *et al*: Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene 31: 671-682, 2012.
- 19. Katsuno Y, Ehata S, Yashiro M, Yanagihara K, Hirakawa K and Miyazono K: Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-β. J Pathol 228: 391-404, 2012.

- 20. Nishikawa S, Konno M, Hamabe A, *et al*: Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. Int J Oncol 42: 1437-1442, 2013.
- Rocco A, Liguori E, Pirozzi G, *et al*: CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors. J Cell Physiol 227: 2686-2693, 2012.
- 22. Ponti D, Costa A, Zaffaroni N, *et al*: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511, 2005.
- Zola H: Medical applications of leukocyte surface molecules - the CD molecules. Mol Med 12: 312-316, 2006.
- 24. da Cunha JP, Galante PA, de Souza JE, *et al*: Bioinformatics construction of the human cell surfaceome. Proc Natl Acad Sci USA 106: 16752-16757, 2009.
- 25. Kreso A, O'Brien CA, van Galen P, *et al*: Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339: 543-548, 2013.
- Dieter SM, Ball CR, Hoffmann CM, *et al*: Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9: 357-365, 2011.